| Literature DB >> 31852481 |
Neusa Bay1, Edna Juga2, Carlos Macuacua3, José João3, Maria Costa3, Simon Stewart4,5, Ana Mocumbi6,7.
Abstract
BACKGROUND: Management of hypertension in Mozambique is poor, and rates of control are amongst the lowest in the world. Health system related factors contribute at least partially to this situation, particularly in settings where there is scarcity of resources to address the double burden of infectious and non-communicable diseases. This study aimed to assess the management of hypertension in an emergency department (ED).Entities:
Keywords: Affordability; Management Cascade; Medicine availability; Systemic hypertension
Mesh:
Substances:
Year: 2019 PMID: 31852481 PMCID: PMC6921411 DOI: 10.1186/s12913-019-4820-8
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Flow of Patients. Describes the flow of the patient with hypertension from arrival at the ED to discharge, indicating the number of hypertensive patients that were seen during the MOZART study
Fig. 2Human Resources Availability. The distribution of health professionals involved in patient care and administrative roles in this health facility is presented, including personnel allocated to NCD complementary services. The numbers are shown per type of services needed
Hypertension Medicines Availability. Drugs and formulations prescribed to patients with hypertension, its estimated need and availability in the hospital
| Therapeutic Group | Generic Name / International Nonproprietary Name | Pharmaceutical form | Strength | Posology | Estimated need for one month | % of medicines available | SDG EM Target Availability |
|---|---|---|---|---|---|---|---|
| Thiazide diuretic + potassium sparing diuretic | Hydrochlorothiazide Amiloride | Tablets | 50 mg + mg | 0,5 | 7905 | 0% | < 80% |
| Angiotensin Converting Enzyme Inhibitor | Lisinopril | Tablets | 20 mg | 1 | 15,810 | 0% | < 80% |
| Calcium Channel Antagonists | Nifedipine | Tablets | 30 mg | 1 | 15,810 | 145% | |
| Calcium Channel Antagonists | Nifedipine | Tablets | 60 mg | 1 | 15,810 | 0% | < 80% |
| Beta blocker | Bisoprolol | Tablets | 5 mg | 1 | 15,810 | 0% | < 80% |
| Beta blocker | Atenolol | Tablets | 50 mg | 0,5 | 7905 | 0% | < 80% |
| Angiotensin-II Receptor Antagonist | Irbesartan | Tablets | 300 mg | 1 | 15,810 | 0% | < 80% |
| Angiotensin Converting Enzyme Inhibitor | Enalapril | Tablets | 20 mg | 1 | 15,810 | 60% | < 80% |
| Adrenergic modifier / alpha 2 agonist | Methyldopa | Tablets | 250 mg | 1 | 15,810 | 51% | < 80% |
| Aldosterone antagonist | Spironolactone | Tablets | 25 mg | 1 | 15,810 | 6% | < 80% |
| Loop diuretic | Furosemide | Tablets | 40 mg | 1 | 15,810 | 70% | < 80% |
Obs: The availability was calculated for all patients (527) reported to have hypertension assisted in October 2017 (considering that this number includes the patients transferred from the ED, and medication should be available for all of them). SDG EM: Sustainable Development Goals Essential Medicines
Fig. 3Work days & Affordability of Medicines. The medicines selected corresponded to the different lines of treatment for arterial hypertension and its complications prescribed at a first-referral hospital according to the national medicines formulary. The graph presents data on affordability of anti-hypertensive drugs (when obtained outside the health facility)